(15008931), J. S. W., (15054769), H. T., (15054772), J. A. E., (15054775), N. M. A., (15054778), B. S., (15054781), H. B., . . . (14932995), M. A. D. (2025). Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
Cita Chicago Style (17a ed.)(15008931), James S. Wilmott, et al. Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib Plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. 2025.
Cita MLA (9a ed.)(15008931), James S. Wilmott, et al. Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib Plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. 2025.